Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 04 May 2017 | By Zachary Brennan
The nonprofit industry group Biosimilars Forum is calling on the US Food and Drug Administration (FDA) to clarify that a demonstration of interchangeability represents a distinct requirement for additional data compared to a demonstration of biosimilarity.
The comment, released this week, follows FDA's issuance of draft guidance on biosimilar interchangeability in January and the release of other comments from stakeholders last month, who also sought more clarity from FDA.
Up front, the Forum notes the importance "for stakeholders across the health care industry to understand that the FDA does not have more than one standard of product quality for the approval of biologics and that the safety and efficacy profiles of biosimilars and their corresponding interchangeable biologics are the same."
In addition, the group representing biosimilar developers including Amgen, Pfizer, Teva and others, also points to several terms that appear in the draft guidance that have not been well-defined, such as "switching" and "substitution."
"The Forum believes industry and the public would benefit from the adoption of a glossary to define particular terms related to interchangeability that would supplement the definitions provided in the recently finalized FDA Guidance to Industry: Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product," the comment says.
The Forum also calls on FDA to clarify the difference between physician-initiated switching and independent pharmacy-level substitution, which "has been the source of significant confusion that could hinder the uptake of biosimilars in the marketplace."
The comment also focuses on the data needed to support an interchangeability finding as outlined in the draft, and specific questions from FDA.
Biosimilars Forum Comment
Tags: biosimilars, FDA draft guidance, Biosimilars Forum
Regulatory Focus newsletters
All the biggest regulatory news and happenings.